Linker Information
General Information of This Linker
| Linker ID |
LIN0DYSYU
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
KR1020250002133A Trastuzumab-C-16 Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C67H103N13O17S
|
|||||
| Isosmiles |
CC([C@H](NC([C@@H](NC(CCN1C(C=CC1=O)=O)=O)CCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN2CCC(CC2)CN3C(CCCC)=NC(C3=C(S4)C(C=C4C)=N5)=C5N)=O)=O)C(N[C@@H](CCCNC(N)=O)C(NC6=CC=C(CO)C=C6)=O)=O)C
|
|||||
| InChI |
InChI=1S/C67H103N13O17S/c1-5-6-9-54-76-60-61(62-53(74-63(60)68)43-47(4)98-62)80(54)44-48-18-23-78(24-19-48)26-28-91-30-32-93-34-36-95-38-40-97-42-41-96-39-37-94-35-33-92-31-29-90-27-22-70-55(82)15-14-52(73-56(83)20-25-79-57(84)16-17-58(79)85)65(87)77-59(46(2)3)66(88)75-51(8-7-21-71-67(69)89)64(86)72-50-12-10-49(45-81)11-13-50/h10-13,16-17,43,46,48,51-52,59,81H,5-9,14-15,18-42,44-45H2,1-4H3,(H2,68,74)(H,70,82)(H,72,86)(H,73,83)(H,75,88)(H,77,87)(H3,69,71,89)/t51-,52-,59-/m0/s1
|
|||||
| InChIKey |
GZTOVERNYUDGOG-CCDDRYASSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
1394.702
|
Polar area
|
392.04
|
||
|
Complexity
|
3017.231061
|
xlogp Value
|
2.62542
|
|||
|
Heavy Count
|
98
|
Rot Bonds
|
51
|
|||
|
Hbond acc
|
23
|
Hbond Donor
|
9
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
Trastuzumab-C-16 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.018 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-16 was tested in HCC1954,80ul,18ᆬh
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.15 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-16 was tested in NCI-N87,80ul,18ᆬh
|
||||
| In Vitro Model | Gastric tubular adenocarcinoma | NCI-N87 cells | CVCL_1603 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.61 nM
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-16 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Emax (TNF-a) |
411.5 pg/mL
|
High HER2 expression (HER19 +++) | ||
| Method Description |
Trastuzumab-C-16 was tested in HCC1954 and PBMC,50ul,24h
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC1954 cells | CVCL_1259 | ||